NOT ALL CATHETERS ARE CREATED EQUAL.

TRUST POWERWAND

✓ SHOWN TO INHIBIT BACTERIAL ATTACHMENT (IN VITRO)¹
✓ SHOWN TO REDUCE THROMBUS FORMATION (IN VIVO)²
✓ OVER 35,000 CATHETER DAYS WITH ZERO BSIs³
✓ FAST AND EASY INSERTION
✓ ONE STICK HOSPITALIZATION
✓ UNPARALLELED POWER INJECTION PERFORMANCE (8ML/SEC, 325 PSI)
✓ KINK RESISTANCE
✓ HIGH FLOW (130-180 ML/MIN)
✓ BLOOD DRAWABILITY

WWW.ACCESSSCIENTIFIC.COM  CS@ACCESSSCIENTIFIC.COM  (858) 259-8333
THE POWERWAND – A CATHETER WITHOUT EQUAL.

Infection Prevention:
Zero BSIs over 35,000 catheter-days (and counting)‡
Catheter material: ChronoFlex C® with BioGUARD™ Technology is proven to inhibit bacterial attachment (in vitro)¹

Cost Savings:
Due to its performance, the POWERWAND resulted in an estimated $448,000-$531,570 of annual savings⁴,⁵

Blood Drawability:
60-99%‡ blood drawability for full length of stay

Echogenic:
Echogenic properties of POWERWAND catheter allows for ultrasound visualization once in the vein

High Flow:
Highest flow rates of any midline catheter: up to 180 mL/min

Power Injection:
The best power injection performance rating on the market: 8mL/sec, 325 psi

Clean:
POWERWAND is shown to inhibit bacterial attachment (in vitro)¹ and is thromboresistant²

Kink Resistant:
Unlike other catheters, the unique material of the POWERWAND catheter is highly kink resistant, allowing for reliability during both insertion and dwell time

Non-Trimmable:
No trimming means a reduction in DVTs⁴; there are no jagged edges on the thermoformed POWERWAND catheter

1. Proven in vitro to significantly (p=0.0133) inhibit bacterial attachment and biofilm formation¹ as compared with a commonly used polyurethane catheter*. 2. The POWERWAND is proven in vivo to be thromboresistant with respect to both thrombus on the surface of the catheter and thrombus on the wall of the vein. Based on canine jugular vein thromboresistance study, correlations to clinical applications has not been ascertained. ¹Based on laboratory test results which may not be indicative of clinical results. Data on file and refer to publication⁰. Preclinical in-vitro evaluations do not necessarily predict clinical performance with respect to catheter-related bloodstream infection. ³ Based on laboratory test results which may not be indicative of clinical results. Data on file and refer to publication⁰. Preclinical in-vitro evaluations do not necessarily predict clinical performance with respect to catheter-related bloodstream infection. ４. Moureau N, Sigl G, Hill M. How to Establish an Effective Midline Program: A Case Study of 2 Hospitals. JAVA 2015; 20(3):179-188. ⁵. Pathak R, Patel A, Enuh H, et al. The Incidence of Central Line–Associated Bacteremia After the Introduction of Midline Catheters in a Ventilator Unit Population. Infect Dis Clin Pract 2015;23(3): 131-134.

* PowerGlide® (CR Bard, Salt Lake City, UT) - a registered trademark of C.R. Bard. POWERWAND™ and BioGUARD™ are trademarks of Access Scientific, LLC. ChronoFlex C® is a registered trademark of AdvanSource Biomaterials Corp.  ‡Data on File.

†Based on laboratory test results which may not be indicative of clinical results. Data on file and refer to publication⁰. Preclinical in-vitro evaluations do not necessarily predict clinical performance with respect to catheter-related bloodstream infection.